We are live on ! Find out more
XERS icon

Xeris Biopharma Holdings

30 hedge funds and large institutions have $184M invested in Xeris Biopharma Holdings in 2018 Q2 according to their latest regulatory filings, with 30 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

48.45% more ownership

Funds ownership: 0%48.45% (+48%)

Holders
30
Holders Change
+30
Holders Change %
% of All Funds
0.69%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
30
Increased
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
PHK
26
Point72 Hong Kong
Hong Kong
$89K +$90.8K +4,670 New
Victory Capital Management
27
Victory Capital Management
Texas
$57K +$58.3K +3,000 New
Morgan Stanley
28
Morgan Stanley
New York
$13K +$14.1K +723 New
CSS
29
Cubist Systematic Strategies
Connecticut
$12K +$12.5K +645 New
UBS Group
30
UBS Group
Switzerland
$9K +$9.06K +466 New
CCA
31
Catalyst Capital Advisors
New York
$7K +$7.25K +373 New

XERS Hedge Fund Activity: Q2 2018 in Review

30 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q2 2018, worth a combined $184M.

Buyers outnumbered sellers: 30 funds opened new XERS positions and 0 closed out — a net gain of 30 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Deerfield Management, opening a new position worth an estimated $48.6M.

  • 30 institutional investors held Xeris Biopharma Holdings (XERS) as of Q2 2018, up from 0 in Q1 2018.
  • Funds reported $184M of Xeris Biopharma Holdings stock for Q2 2018.
  • 30 funds opened new Xeris Biopharma Holdings positions in Q2 2018 and 0 closed out, a net change of +30 holders.
  • The largest Xeris Biopharma Holdings buyer in Q2 2018 was Deerfield Management, an estimated $48.6M added.

Based on aggregated 13F filings for Q2 2018.